The current asthma treatment guidelines recommend using medicines that control airway inflammation, rather than relying only on inhalers that provide quick relief. The 2026 Global Initiative for Asthma (GINA) strategy is the main international reference, supported by newer recommendations from the American Thoracic Society (ATS) and the World Health Organization (WHO). Treatment depends on age, asthma control, the risk of flare-ups, and individual response to medication.
Which asthma treatment guidelines are currently used?
Several professional organizations publish evidence-based recommendations for asthma care. They share important treatment principles, although their recommendations may differ by age group, healthcare system, and available medications.
Global Initiative for Asthma (GINA) 2026
The Global Initiative for Asthma (GINA) 2026 Strategy Report is the latest international framework for asthma diagnosis, treatment, and prevention as of November 2026. GINA reviews new medical research regularly and updates its recommendations to reflect changes in asthma treatment.
Its central recommendations include:
- Using inhaled corticosteroid-containing treatment for adults, adolescents, children, and most preschool children with asthma.
- Avoiding treatment with a short-acting bronchodilator alone.
- Using inhaled corticosteroid-formoterol as the preferred reliever approach for most adults and adolescents.
- Adjusting treatment according to symptom control, the risk of asthma attacks, and medication response.
- Providing education, correct inhaler training, and a written asthma action plan.
American Thoracic Society (ATS) 2026 recommendations
On November 3, 2026, the American Thoracic Society published a new clinical practice guideline on inhaled corticosteroid-containing reliever treatment for adolescents and adults.
The guideline recommends anti-inflammatory reliever treatment, using either an inhaled corticosteroid-formoterol combination or inhaled corticosteroid with a short-acting bronchodilator, rather than a short-acting bronchodilator alone for people in treatment steps 1 and 2. For treatment steps 3–5, it strongly recommends maintenance-and-reliever therapy with inhaled corticosteroid-formoterol over a separate maintenance inhaled corticosteroid-LABA inhaler and short-acting reliever combination.
These recommendations add recent evidence to the existing asthma treatment framework. They specifically address reliever medication and do not replace the need for a comprehensive asthma management plan.
National Asthma Education and Prevention Program (NAEPP)
In the United States, the National Asthma Education and Prevention Program (NAEPP), supported by the National Heart, Lung, and Blood Institute (NHLBI), issued focused asthma guideline updates in 2020.
These updates address six important areas, including inhaled corticosteroid use, additional bronchodilator treatment, indoor trigger reduction, allergy immunotherapy, fractional exhaled nitric oxide testing, and bronchial thermoplasty. They update selected areas of the older asthma guidelines rather than replacing the entire previous framework.
The NHLBI asthma management guideline update remains an important reference for understanding treatment recommendations in the United States.
World Health Organization (WHO) childhood asthma guidelines
The WHO published updated consolidated guidance for asthma in children and adolescents on May 7, 2026. It covers children and young people aged 0–19 years, including long-term treatment, inhaled corticosteroids, maintenance-and-reliever therapy, and the management of acute asthma attacks.
The guidance also considers treatment affordability, access to medicines, and the practical needs of healthcare systems, particularly in countries with limited healthcare resources. The WHO childhood asthma guidelines provide an additional reference for pediatric asthma management.
What are the main principles of current asthma treatment?
Modern asthma guidelines focus on controlling airway inflammation, preventing future attacks, and maintaining normal daily activities. Treatment is not based only on how often a person experiences wheezing or breathlessness.
1. Inhaled corticosteroids are central to treatment
Inhaled corticosteroids (ICS) are anti-inflammatory medicines that reduce swelling and inflammation inside the airways. They help prevent symptoms and reduce the risk of asthma flare-ups.
Common inhaled corticosteroids include budesonide, beclometasone, fluticasone, and ciclesonide. They may be prescribed in an inhaler containing only a corticosteroid or combined with another asthma medicine.
Current GINA recommendations support ICS-containing treatment across asthma age groups. The exact medicine, dose, and schedule depend on the person's treatment needs.
2. Short-acting reliever inhalers should not be the only treatment
Short-acting beta-2 agonists (SABA), such as salbutamol, also called albuterol in some countries, relax the muscles around the airways. They can provide quick relief when breathing symptoms occur.
However, these medicines do not treat the underlying airway inflammation. Using a SABA inhaler alone can leave that inflammation untreated and does not provide the same protection against severe asthma attacks as an ICS-containing treatment plan.
For this reason, current guidelines recommend an approach that provides anti-inflammatory treatment along with symptom relief. A SABA may still be used in certain treatment plans, but it should not automatically be the only asthma medicine.
3. Treatment should be adjusted regularly
Asthma control can change over time. A treatment plan that works well during one period may need adjustment when symptoms, lung function, or the risk of flare-ups changes.
GINA uses an ongoing process known as Assess, Adjust, Review:
- Assess: Review symptoms, previous asthma attacks, lung function, inhaler technique, medication use, other health conditions, and individual treatment goals.
- Adjust: Modify medication or other management measures when necessary.
- Review: Check whether treatment is improving symptoms and reducing the risk of future attacks.
This approach helps healthcare professionals select the lowest effective treatment intensity while maintaining good asthma control.
What are the current asthma treatment steps for adults and adolescents?
For adults and adolescents aged 12 years and older, GINA recommends a stepwise approach. Treatment generally becomes more intensive when symptoms remain uncontrolled or the risk of exacerbations remains high.
GINA describes two treatment pathways, called Track 1 and Track 2. Track 1 is the preferred approach for most adults and adolescents because it uses an inhaled corticosteroid-formoterol combination as the reliever.
Track 1: Preferred treatment approach
Track 1 uses a combination of an inhaled corticosteroid and formoterol. Formoterol is a long-acting bronchodilator with a rapid onset of action, allowing certain combination inhalers to provide both anti-inflammatory treatment and quick symptom relief.
The treatment pathway generally includes the following steps:
- Steps 1–2: Low-dose ICS-formoterol is taken when needed for symptom relief. This is called anti-inflammatory reliever-only treatment, or AIR-only.
- Step 3: Low-dose ICS-formoterol is taken regularly for maintenance treatment, with additional doses of the same inhaler when symptoms occur.
- Step 4: A higher maintenance treatment intensity, generally using medium-dose ICS-formoterol, is prescribed, with the same inhaler available for symptom relief.
- Step 5: Specialist assessment is recommended to investigate difficult-to-treat or severe asthma and consider additional treatment options.
When the same ICS-formoterol inhaler is used regularly and for symptom relief, the approach is called maintenance-and-reliever therapy (MART). In some countries, this is also known as single maintenance and reliever therapy (SMART).
MART is different from simply using two separate inhalers. It uses a suitable ICS-formoterol combination for both purposes. Other ICS-LABA combinations that do not contain formoterol cannot be used in the same way.
Track 2: Alternative treatment approach
Track 2 may be considered when the preferred ICS-formoterol treatment is unavailable, unsuitable, or not chosen for an individual patient.
Depending on available medicines, the approach may include:
- Step 1: As-needed low-dose ICS-SABA treatment, either in a combination inhaler or as separate inhalers taken together. If only a SABA reliever is available, the patient needs an appropriate inhaled corticosteroid strategy whenever the reliever is used.
- Step 2: Daily low-dose inhaled corticosteroid treatment with an appropriate reliever.
- Step 3: Daily low-dose ICS-LABA treatment with an appropriate reliever.
- Step 4: Daily medium-dose ICS-LABA treatment with an appropriate reliever.
- Step 5: Specialist assessment and consideration of additional treatment for severe asthma.
Patients using separate controller and reliever inhalers need to understand when and how to use each one. Regular use of the prescribed controller is important, particularly when the reliever does not contain an inhaled corticosteroid.
The GINA 2026 Summary Guide provides the detailed treatment pathways, including recommended approaches for adults, adolescents, and children aged 6–11 years.
How do asthma treatment guidelines differ for children?
Children need age-appropriate asthma treatment. The choice of inhaler, medication, and treatment schedule depends on the child's age, symptoms, medical history, and ability to use an inhaler correctly.
Children aged 6–11 years
GINA recommends ICS-containing treatment for children aged 6–11 years rather than treatment with a SABA alone.
The treatment options depend on the child's symptoms and asthma history:
- Step 1: As-needed low-dose ICS-formoterol or ICS-SABA may be used as an anti-inflammatory reliever.
- Step 2: Daily low-dose inhaled corticosteroid treatment is a preferred option.
- Steps 3–4: Options include daily ICS, ICS-LABA combinations, or suitable ICS-formoterol maintenance-and-reliever treatment.
- Step 5: Children who need more intensive treatment may require specialist assessment and additional therapies.
For children who need higher treatment steps, a pediatric asthma specialist may help determine whether the diagnosis, treatment choice, and inhaler technique need further review.
Children younger than 6 years
Preschool children need a separate assessment and treatment approach. Recurrent wheezing in young children can have different causes, and diagnosing asthma may be more challenging than in older children.
GINA recommends ICS-containing treatment for most preschool children with asthma. The exact approach depends on the child's clinical history and pattern of symptoms. Medication delivery may also require an age-appropriate inhaler and spacer or mask.
The WHO's 2026 guidance provides additional recommendations for asthma treatment and acute exacerbation management in children and adolescents, including younger age groups.
What happens when asthma is not controlled with standard treatment?
When asthma symptoms continue despite prescribed medication, increasing the dose immediately is not always the best first step. Healthcare professionals generally review several possible reasons for poor control before changing the treatment plan.
These checks may include:
- Incorrect inhaler technique: Poor inhaler technique can prevent the medicine from reaching the airways effectively.
- Missed medication: Regularly missing prescribed controller doses may reduce the benefits of treatment.
- Ongoing exposure to triggers: Tobacco smoke, vaping, indoor allergens, outdoor air pollution, and workplace irritants may contribute to worsening symptoms.
- Other medical conditions: Conditions such as allergic rhinitis, obesity, or gastroesophageal reflux may contribute to ongoing respiratory symptoms or make asthma harder to control.
- Unconfirmed diagnosis: Other respiratory or medical conditions can sometimes cause symptoms that resemble asthma.
After reviewing these factors, the healthcare professional may adjust the inhaled medication, change the treatment pathway, or arrange further testing.
What treatments are recommended for severe asthma?
Severe asthma is asthma that remains uncontrolled despite appropriate high-intensity treatment, or that requires such treatment to maintain control. It needs a more detailed assessment than simply increasing the dose of a standard inhaler.
When severe asthma is suspected, specialists may investigate the type of airway inflammation and consider treatments based on the person's asthma characteristics.
Additional inhaled medicines
A long-acting muscarinic antagonist (LAMA), such as tiotropium, may be added to an existing inhaled treatment plan for selected patients whose asthma remains uncontrolled.
Some patients may also need an adjustment to their existing inhaled corticosteroid-LABA treatment, following an assessment of the benefits and possible side effects.
Biologic medicines
Biologic medicines are targeted treatments that act on particular parts of the immune system involved in asthma inflammation. They may be considered for selected people with severe asthma when standard treatment has not provided sufficient control.
Depending on the type of asthma and clinical assessment, available options may include:
- Anti-IgE treatment: For selected patients with severe allergic asthma.
- Anti-IL-5 or anti-IL-5 receptor treatment: For selected patients with severe eosinophilic asthma.
- Anti-IL-4 receptor treatment: For selected patients with severe Type 2 inflammatory asthma or certain other severe asthma patterns.
- Anti-TSLP treatment: An option for selected patients with severe asthma.
The choice depends on clinical findings, inflammatory markers, previous treatment response, age, eligibility criteria, and local availability. These medicines are not necessary for most people with asthma.
Why should long-term oral steroids be avoided when possible?
Oral corticosteroids, such as prednisolone, can be important during certain severe asthma flare-ups. However, repeated courses and long-term use can cause significant side effects.
Current GINA recommendations advise reserving maintenance oral corticosteroids for situations in which other suitable treatments have not provided adequate control. Healthcare professionals aim to reduce the need for repeated steroid courses through appropriate inhaled treatment, correct inhaler technique, and other suitable therapies.
What non-medicine measures are included in asthma guidelines?
Medication is central to asthma treatment, but guidelines also support practical measures that help people manage their condition and reduce preventable flare-ups.
Inhaler education and correct technique
Patients should be shown how to use their prescribed inhaler correctly. Technique should be checked periodically because even small errors can reduce the amount of medicine reaching the lungs.
Reducing exposure to relevant triggers
Management may include avoiding tobacco smoke and vaping, reducing exposure to identified allergens, and addressing irritants at home or work. Avoidance measures should be based on relevant exposures rather than unnecessary restrictions.
Written asthma action plans
GINA recommends that people with asthma have an individualized written, digital, or pictorial asthma action plan. This plan explains:
- Which medicines to use during usual daily management.
- What changes to make when asthma symptoms begin to worsen.
- When additional medical advice is needed.
- When to seek urgent or emergency medical care.
The plan should match the person's prescribed treatment and should be reviewed when medications change. It is particularly important for parents and caregivers managing asthma in children.
How often should asthma treatment be reviewed?
Asthma requires ongoing follow-up, even when symptoms are well controlled. Reviews help determine whether treatment remains appropriate and whether the person is experiencing medication side effects or ongoing risk of flare-ups.
During a review, healthcare professionals may assess:
- Daytime symptoms and nighttime waking.
- Use of the reliever inhaler.
- Previous asthma attacks, emergency visits, or hospital admissions.
- Medication adherence and inhaler technique.
- Lung function, when appropriate.
- Possible triggers, other health conditions, and treatment side effects.
If asthma is not well controlled, the treatment plan may need to be stepped up after these factors have been reviewed. When good control has been maintained for at least 2–3 months, a healthcare professional may consider gradually reducing treatment to find the lowest effective level.
Inhaled corticosteroid treatment should not be stopped completely in adults and adolescents simply because symptoms have improved. Any reduction should follow an appropriate treatment plan.
Do current asthma treatment guidelines apply equally in every country?
No. International guidelines provide evidence-based recommendations, but the medicines and treatment options available can differ between countries.
Differences may relate to medication approvals, inhaler availability, healthcare costs, local clinical recommendations, and access to specialist treatment. For example, some countries may not have access to every ICS-formoterol or ICS-SABA combination recommended in international treatment pathways.
In these situations, healthcare professionals may use an appropriate alternative that still provides inhaled corticosteroid treatment and adequate symptom relief. The best treatment plan should follow current local recommendations while considering the principles of international asthma guidelines.
When should someone seek medical help for worsening asthma?
People with asthma should follow their written action plan when symptoms become worse. Increasing breathlessness, persistent wheezing, worsening chest tightness, or a growing need for reliever medication may indicate that asthma control is deteriorating.
Severe breathing difficulty, inability to speak normally because of breathlessness, or little improvement after using the prescribed reliever requires emergency medical attention. A person should not delay urgent care while waiting for routine follow-up.
After an asthma attack that requires emergency treatment or hospital care, follow-up is important to review long-term treatment and update the action plan where necessary.
What is the main takeaway from the current asthma guidelines?
The major direction of modern asthma treatment is to combine symptom relief with control of airway inflammation. The 2026 GINA recommendations favor ICS-formoterol reliever treatment for most adults and adolescents, while age-specific pathways guide treatment in children. The newer ATS recommendations further support ICS-containing reliever therapy, and WHO provides updated pediatric guidance.
Good asthma management involves more than choosing an inhaler. Regular assessment, correct inhaler technique, appropriate treatment adjustments, and a written action plan all contribute to better long-term control and a lower risk of severe attacks.